The PennZone

  • Home
  • Non-profit
  • Books
  • Health
  • Marketing
  • Entertainment
  • Sports
  • Business
  • Legal

BIOLASE ANNOUNCES SUPPORT FOR PROJECT HOME
The PennZone/10188856

Trending...
  • Bountiful Bowl Aims to Raise $50,000 to Support Meals on Wheels of the Greater Lehigh Valley
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
  • WebDrafter Welcomes Dreamwork Exteriors as a New Marketing Client
LAKE FOREST, Calif., June 27, 2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that it has partnered with Project HOME, an organization that provides dental services to patients from their first birthday to adulthood. Project HOME's Healthcare Services is a Federally Qualified Health Center (FQHC) and supports health care services, regardless of a person's ability to pay for the services, in Philadelphia.

The mission of Project HOME is to empower adults, children, and families to break the cycle of homelessness and poverty, alleviate the underlying causes of poverty, and enable individuals to attain their fullest potential as individuals and as members of the broader society. Project HOME strives to create a safe and respectful environment to support individuals struggling with self-esteem, recovery, confidence, as well as mental and physical health.

Project HOME's dental services are part of a patient-centered, integrated health care service model, where many dental patients are also primary care patients. This allows medical issues that may impact oral health to be identified early and for treatment to begin to improve the patients' overall well-being.

During a ride-along with the BIOLASE team in Philadelphia, BIOLASE's President and Chief Executive Officer, John Beaver, was invited to visit Project HOME to see how the company could assist people in need. "At BIOLASE, our goal is to develop dental laser technology that provides a higher standard of care to the patient and improves patients' oral health," said Beaver. "Supporting Project HOME in their mission gives BIOLASE an opportunity to make a meaningful contribution to the overall health of the community."

"It is a great honor that BIOLASE has partnered with Project HOME to help provide dental care to our members. With the donation of an iPlus Waterlase laser system and the training program offered to our doctors and staff at Project HOME's dental facility in Philadelphia, the modern technology offered by BIOLASE will help provide a new standard of care for Project HOME members," commented Dr. Janine Burkhardt, Project HOME's Dental Director. "Improving the already excellent care each member receives, while assisting the doctors to complete more treatments in one visit, will have a significant impact on our ability to achieve our mission and improve our members' oral health outcomes."

More on The PennZone
  • P-Wave Press Announces Becoming Dad: Reflections for New Fathers by L. A. Davenport
  • Logicraft Launches FuelDeck™, AI That Turns Aviation Fuel Tickets Into One Traceable Ledger
  • Inaugural OC Tech Week Draws 3,000 From 12 Countries, Sends Finalist to $1M Startup World Cup
  • Award-Winning American Hotelier Opens Art-Filled Luxury Cottage in Norfolk, England
  • K2 Global / Ozi Amanat Named Among Top 100 AI Venture Capitalists in 2026

About Project HOME

Since 1989, Project HOME has helped thousands of people break the cycle of homelessness and poverty by providing a continuum of care that includes street outreach, supportive housing and comprehensive services that focus on health care, education and employment through both adult and youth education and enrichment programs. To learn more, visit www.projecthome.org.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 301 patented and 32 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 43,300 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

More on The PennZone
  • Dr. Latorial Faison Appointed Poet Laureate of Virginia
  • AdLeverage Brings Golf Simulator Contest and Home Services Marketing Expertise to Service World Expo 2026
  • Cleveland Factory Worker Seeks Funding for AI-Readable Archive Exploring Advanced AI Restraint and Human Survival
  • Ten Ten Ten Announces Maximizing Quality Performance, a Value-Based Care Implementation Guide
  • Hunter's Garage Teams Up With The Small Batch for a Free Thanksgiving Meal

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding the anticipated roll out of new go-to-market sales strategies, the Company's efforts to achieve its goal of becoming EBITDA positive. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," "should," and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described, from time-to-time, in the "Risk Factors" section of BIOLASE's annual reports filed on Form 10-K with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

For further information, please contact:
EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
[email protected] / [email protected]

SOURCE BIOLASE, Inc.
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Conservative Latinos for PA PAC Endorses Stacy Garrity for Governor: "Pennsylvania's Latino Families Need a Leader Who Delivers"
  • AthleteMerch.com Surpasses 100,000 Custom Items Delivered to Fans Nationwide
  • MoMojo Records Signs Gary Nicholson
  • Steve Weclew is Appointed by STS Capital Partners as Managing Director
  • Communities In Schools of Eastern Pennsylvania Honors United Way and Local Leaders
  • New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
  • Veterans Day Breakfast Celebration in Valley Forge to Honor America's Military Heroes
  • Best Black Friday 2026 Deals on Lightweight Foldable Electric Wheelchairs – Save Up to 60%
  • Immerse Yourself in the Historic Tochigi Autumn Festival, Celebrated Every Two Years Since 1874
  • Resident Inspect Expands Virtual Property Inspections With AppFolio and Rentvine Integrations
  • Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA)
  • Dr. Marilyn Pendelton Releases The Grief Reset to Address Grief Beyond Death
  • AeroNet Deploys netElastic vBNG and CGNAT with Tarana Wireless to Deliver Scalable, Fiber-Class Broadband Across Puerto Rico
  • New Atlas Maps the 38 States Behind Every Conversation
  • Atlanta Company Launches Free, Ad-Free, Nonpartisan Voter Planning App for All 50 States Ahead of the Nov. 3 Election
  • Pastor Carlton L. Aiken Sr. Celebrates 55 Years with "Sermonic Selections"
  • J. Wes Seeks Jazz Musicians, Vocalists and Bands for Philadelphia Live Music Event
  • NECP Promotes Chertova to Senior Business Analyst
  • Security Industry Veteran Anthony Rumore Launches AegisLead to Help Security Companies Find Business and Manage Growth

Popular on PennZone

  • SMACK Fighting Championships Announces Influencer Fight Night at Harrah's Philadelphia - 208
  • ASSIST Software Wins Volkswagen Challenge for Automated Quality Inspection - 102
  • New Children's Picture Book "Tippy Tay" Explores the Dangers of Peer Pressure and the Importance of
  • New Children's Picture Book "Adam's Apple" Celebrates Childhood Curiosity and the Funny Misundersta
  • RAS AP Consulting Issues National Compliance Alert and Launches Q4 2026 AP Readiness Program Ahead of IRS FIRE → IRIS Cutover
  • Free Senior Housing Webinar Helps Families Plan for Aging Before a Crisis Forces Difficult Decisions
  • LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports
  • What Mold Remediation Costs in Gettysburg, PA: 2026 Price Ranges by Job Type
  • Pittsburgh Digital Marketing Agency Moves to Babcock Boulevard in the North Hills
  • Corner Property Management AAMC Expands Presence with Clover Mill Management Agreement

Similar on PennZone

  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA
  • K2 Global / Ozi Amanat Named Among Top 100 AI Venture Capitalists in 2026
  • Pursant Founder Mark Herbick Joins STS Capital Partners as CEO
  • Tampa Web Design Launches New Website for Entrepreneur and Capital Markets Advisor Martin Sumichrast
  • UK Financial Ltd. Announces Maya Preferred PRA as First Fully Verified Asset on MAYA CHAIN; Chainlink Proof of Reserve Integration Planned for Network
  • RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
  • Steve Weclew is Appointed by STS Capital Partners as Managing Director
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
  • Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA)
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us